Liraglutide (Saxenda) at 3.0 mg once daily produces roughly 5–8% mean total weight loss — meaningful, but less than the weekly agents semaglutide (~15%) or tirzepatide (up to ~21%). It is a daily injection with a long safety record and, in diabetes, a proven cardiovascular benefit (LEADER). Results are averages; individual response varies.
Obesity Medication Library entry. Section accent: family --teal.
DRUG FACT PANEL
| Generic | Liraglutide |
| Brands | Saxenda (chronic weight management, 3.0 mg/day), Victoza (type 2 diabetes, up to 1.8 mg/day) |
| Class | GLP-1 receptor agonist (short-acting; once daily) |
| Mechanism (1 line) | Mimics the gut hormone GLP-1 — increases satiety, reduces appetite, slows gastric emptying, improves glucose |
| FDA indications | Chronic weight management (Saxenda); type 2 diabetes (Victoza) |
| Who it's for | Adults (and, for Saxenda, eligible adolescents) who want or need an incretin but a daily regimen — or who tolerate liraglutide better than a weekly agent |
| Route/formulation | Subcutaneous injection, once daily |
| Titration concept | Started low and increased stepwise over weeks to limit GI effects — individual dosing is set by a clinician, not this page |
| Expected effect | ~5–8% mean total weight loss — less than weekly semaglutide or tirzepatide |
| Evidence level (obesity) | Grade A 🟢 — RCTs + guideline support; lower efficacy than weekly agents |
What liraglutide is
Liraglutide is an older, once-daily GLP-1 receptor agonist — the same drug class as semaglutide, but a shorter-acting molecule that must be injected every day rather than weekly. It is sold as Saxenda (3.0 mg) for weight management and Victoza (up to 1.8 mg) for type 2 diabetes. It was among the first incretins used for obesity and remains a reasonable option, though the weekly agents have largely overtaken it on average efficacy and convenience. → GLP-1 & Incretin Medications
How it works
Like all GLP-1 agonists, liraglutide acts on receptors in the brain and gut to increase fullness, reduce hunger and food preoccupation, slow gastric emptying, and improve glucose control (stimulating insulin mainly when glucose is elevated, so it rarely causes low blood sugar on its own). Its shorter half-life is the main reason it is dosed daily and, on average, produces less weight loss than longer-acting weekly drugs. → Why Weight Is So Hard to Lose
What the trials actually show
Weight (obesity): liraglutide 3.0 mg daily produces about 5–8% mean total weight loss over roughly a year — clinically useful, but consistently below weekly semaglutide (~15% in STEP 1) and tirzepatide (up to ~21% in SURMOUNT-1). → Semaglutide · Tirzepatide
Cardiovascular (diabetes) — LEADER: in adults with type 2 diabetes at high cardiovascular risk, liraglutide reduced major adverse cardiovascular events. This is a diabetes outcome trial — a genuine benefit, but distinct from semaglutide's SELECT trial, which showed CV benefit in people with obesity without diabetes. → Obesity & Cardiovascular Health
Side effects
Common (mostly GI, dose-related, usually improve): nausea, vomiting, diarrhoea, constipation, reflux, burping, fatigue, injection-site reactions. Daily injection means daily local reactions are possible. Managed with slow titration, smaller and lower-fat meals, and hydration. → GLP-1 Side Effects
Less common / serious: gallstones and gallbladder disease (more likely with rapid weight loss), pancreatitis (rare), dehydration and kidney injury from severe GI symptoms. Muscle and lean-mass questions are covered separately. → GLP-1 & Muscle Loss
Contraindications & cautions
- Personal or family history of medullary thyroid carcinoma, or MEN2 — contraindicated (boxed warning, shared across the GLP-1 class; based on rodent C-cell tumours, not established in humans).
- History of pancreatitis — caution.
- Active severe GI disease / gastroparesis — caution.
- Pregnancy — not recommended (see below).
Monitoring, pregnancy and surgery
- Monitoring: response (weight, and glucose/A1c in diabetes), GI tolerance, and — because muscle preservation matters — attention to protein intake and resistance training. → Exercise, Muscle & Body Composition
- Pregnancy/lactation: not recommended in pregnancy; discontinue if pregnancy is planned or confirmed. Liraglutide's short half-life means it clears faster than the long-acting weekly agents, but it should still be stopped. → Women's Health & Obesity
- Perioperative: GLP-1s slow gastric emptying; anaesthesia guidance has moved toward holding them before surgery or procedures. Follow your surgical/anaesthesia team's current instructions.
Long-term considerations, discontinuation and weight regain
Like every effective obesity medication, liraglutide treats a chronic disease: its effect depends on continued use. Stopping is typically followed by weight regain as the body's defended set point reasserts itself — the same pattern seen with the weekly agents, and not a personal failure. Maintenance should be planned before starting, and any switch (for example to a weekly agent for greater efficacy or convenience) is a clinical decision. → Weight Regain & Maintenance
Unanswered questions
- Long-term durability and safety relative to the weekly incretins.
- Whether daily dosing offers any tolerability advantage for specific patients.
- Best role now that more potent weekly agents exist.
Questions patients ask
How much weight will I lose on Saxenda?
About 5–8% on average over roughly a year — meaningful, but less than weekly semaglutide or tirzepatide. It's an average, not a personal guarantee. Grade A 🟢
Is liraglutide the same as Ozempic or Wegovy?
Same drug class (GLP-1 agonist) but a different, shorter-acting molecule — liraglutide is daily, semaglutide is weekly and generally more potent. Grade A 🟢 → Semaglutide
Why would anyone choose a daily injection over a weekly one?
Tolerability, prior experience, access or cost can all favour liraglutide for a given person; some tolerate it better. "More potent" isn't automatically "better for you." Grade B 🟡
Does liraglutide protect the heart?
In type 2 diabetes, the LEADER trial showed a cardiovascular benefit. That's a diabetes population — distinct from semaglutide's CV benefit shown in obesity without diabetes. Grade A 🟢 (diabetes) → Obesity & Cardiovascular Health
Is Saxenda the same as Victoza?
Same molecule, different brand and dose — Saxenda (3.0 mg) for weight, Victoza (up to 1.8 mg) for diabetes. Grade A 🟢
Will I regain weight if I stop?
Usually yes — stopping is typically followed by regain, as with every effective obesity drug, because the underlying biology persists. Grade A 🟢 → Weight Regain & Maintenance
KEEP READING
- Obesity Medication Library — how liraglutide compares with every approved option.
- Semaglutide and Tirzepatide — the more potent weekly incretins.
- GLP-1 Side Effects — every concern, graded.
- Weight Regain & Maintenance — the "forever" question, for any obesity drug.
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: Saxenda/Victoza FDA prescribing information; SCALE program (obesity); LEADER (cardiovascular outcomes in type 2 diabetes). Not individualized medical advice.
